Insider Selling: DexCom (NASDAQ:DXCM) EVP Sells $364,052.43 in Stock

DexCom, Inc. (NASDAQ:DXCM) EVP Jon Coleman sold 4,911 shares of the business’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $74.13, for a total transaction of $364,052.43. Following the completion of the sale, the executive vice president owned 95,450 shares in the company, valued at $7,075,708.50. This represents a 4.89% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jon Coleman also recently made the following trade(s):

• On Wednesday, June 3rd, Jon Coleman sold 4,912 shares of DexCom stock. The stock was sold at an average price of $73.00, for a total transaction of $358,576.00.

DexCom Stock Performance

Shares of DXCM opened at $72.86 on Monday. The company’s fifty day moving average is $64.83 and its 200 day moving average is $67.04. DexCom, Inc. has a fifty-two week low of $54.11 and a fifty-two week high of $89.98. The stock has a market capitalization of $28.11 billion, a PE ratio of 31.14, a P/E/G ratio of 1.14 and a beta of 1.45. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.64 and a current ratio of 1.95.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, April 30th. The medical device company reported $0.56 earnings per share for the quarter, topping the consensus estimate of $0.47 by $0.09. DexCom had a net margin of 19.31% and a return on equity of 33.33%. The company had revenue of $1.19 billion for the quarter, compared to analysts’ expectations of $1.17 billion. During the same quarter in the previous year, the business posted $0.32 earnings per share. DexCom’s quarterly revenue was up 15.0% on a year-over-year basis. Sell-side analysts expect that DexCom, Inc. will post 2.57 earnings per share for the current fiscal year.

Trending Headlines about DexCom

Here are the key news stories impacting DexCom this week:

• Positive Sentiment: DexCom announced it will highlight new clinical findings, product advancements, and strategic initiatives at ADA 2026, reinforcing its case for broader CGM adoption and earlier-stage diabetes intervention. Article: Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026
• Positive Sentiment: Recent commentary remained constructive, with analysts and market coverage noting DexCom’s strong Q1 momentum, global CGM growth potential, and expanding international demand, which may help support the stock. Article: Here’s Why You Should Retain DexCom Stock in Your Portfolio
• Positive Sentiment: DexCom also said it plans to acquire wellness tracking company Nutrisense and launch an enhanced Stelo app, a move that could broaden its consumer health footprint and create new engagement opportunities. Article: Dexcom to acquire wellness tracking company Nutrisense, launch enhanced Stelo app
• Neutral Sentiment: DexCom EVP Jon Coleman sold shares in two transactions under a pre-arranged 10b5-1 plan. While the sales were disclosed as routine, insider selling can still weigh on sentiment. Article: SEC Form 4 filing
• Neutral Sentiment: Separate market commentary noted DexCom has lagged the Dow over the past year, even as analysts remain bullish on its longer-term outlook. Article: Is DexCom Stock Underperforming the Dow?

Analyst Ratings Changes

A number of research analysts have weighed in on the stock. BTIG Research reiterated a “buy” rating and set a $85.00 price objective on shares of DexCom in a research report on Monday, March 9th. Wall Street Zen downgraded shares of DexCom from a “strong-buy” rating to a “buy” rating in a research note on Sunday, May 10th. Sanford C. Bernstein set a $77.00 target price on shares of DexCom in a research note on Friday, May 1st. Barclays reissued an “underweight” rating and issued a $64.00 target price (down from $67.00) on shares of DexCom in a research note on Monday, May 18th. Finally, Canaccord Genuity Group set a $82.00 target price on shares of DexCom and gave the company a “buy” rating in a research note on Monday, May 18th. Three analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $82.63.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Reflection Asset Management bought a new position in shares of DexCom in the fourth quarter worth about $25,000. Ascentis Independent Advisors bought a new position in shares of DexCom in the first quarter worth about $25,000. CVA Family Office LLC grew its holdings in shares of DexCom by 48.5% in the fourth quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock worth $30,000 after purchasing an additional 147 shares during the last quarter. MCF Advisors LLC bought a new position in shares of DexCom in the fourth quarter worth about $32,000. Finally, ORG Partners LLC grew its holdings in shares of DexCom by 124.3% in the fourth quarter. ORG Partners LLC now owns 507 shares of the medical device company’s stock worth $34,000 after purchasing an additional 281 shares during the last quarter. 97.75% of the stock is currently owned by institutional investors.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.